Podcasts about Novo

Viajamos no tempo como um ninja, e depois um samurai, e depois um ninja em busca de vingança no receptivo Nioh 3. Comentamos também as demissões e futuro de 2XKO, Overwatch perdendo o número 2, o anúncio de Horizon Hunters Gathering, os resultados do PlayStation e da Obsidian e mais! Comece seu dia com a INSIDER #insiderstore Nosso cupom: JOGABILIDADE 00:08:59: Riot demite desenvolvedores de 2XKO 00:19:34: Blizzard remove o 2 de Overwatch 00:32:47: Novo CEO na Remedy Entertainment 00:34:37: Horizon Hunters Gathering foi anunciado 00:51:48: Resultados do trimestre do Playstation 01:06:26: O preço do Switch 2 01:12:26: Valve adia a Steam Machine 01:16:27: Resultados da Obsidian 01:23:08: Devs de Clair Obscur: Expedition 33 são condecorados 01:33:35: Série de Baldur's Gate 3 da HBO 01:40:38: Nioh 3 02:29:06: Perguntas dos ouvintes 02:42:33: Finalmentes Contribua | Twitter | YouTube | Twitch | Contato

Silver, Gold and Crypto (oh my) Hang on – Wild ride here Superbowl, Olympics- Wait until you hear about the CAPex spending! Shakeup in Dietville PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Interactive Brokers  Warm-Up - Silver, Gold and Crypto (oh my) - Need a stock for CTP - Hang on - Wild ride here - Superbowl, Olympics- Wait until you hear about the CAPex spending! - Shakeup in Dietville Markets - Massive moved during the week - - Bitcoin clipped $60k before rebounding - DJIA tops 50,000 for the first time - Wait until you hear about the CAPex spending! - CAT == 1,100 points on the DJIA in 2026 Superbowl and Superbowl ads - Game review - Any ad stick out? - $10M per ad this year - Half Time with Bad Bunny? - Anthropic busting on OpenAi Last Week! - Massive moved - quick calc showed that about $1T was wiped from market caps in the sell-off, particularly in tech names. - HOWEVER - Friday alone is estimated to have added $1.5T to market cap AI Ripping Through - Plenty of names getting cooked over AI announcements - First it was the software companies - Now there are names in legal and finance that got clocked - Today - Altruist.ai can do tax planning and that hurt companies in financial space Earnings Season Update - Reporting so far: 59% of S&P 500 companies have reported Q4 2025 results. - Beat rate: 76% have topped EPS estimates (vs. 5-yr average: 78% (slightly lower) vs. 10-yr average: 76% (in line) - Magnitude of beats (aggregate): earnings are 7.6% above estimates vs. 5-yr average: 7.7% (about the same) vs. 10-yr average: 7.0% (a bit better) - Nothing great,  like Goldilocks Earnings Highlights - Palantir (PLTR): Reported strong Q4 results early in the week , beating estimates with revenue ~$1.41B (vs. ~$1.33B expected) and EPS $0.25 (vs. $0.23). Guidance for 2026 was upbeat (~61% revenue growth). Shares rallied sharply initially (~7–11% post-earnings), but gave back some gains amid broader tech volatility (e.g., down ~11–22% in parts of the week from peaks). - AMD: Reported mid-week, beating EPS (~$1.53 vs. lower expectations) with solid data center growth (~39%). However, Q1 guidance disappointed relative to high expectations in the AI chip space. Shares sank dramatically — down ~15–17% the next day, with some reports noting up to 20%+ drops at points, contributing to broader chip sector pressure. - Alphabet (GOOGL/GOOG): Reported beating on revenue (~$113.8B) and EPS (~$2.82), with strong core performance. But capex guidance for 2026 ($175–$185B, roughly double prior levels) sparked AI spending worries. Shares dipped post-earnings (down ~0.5–5% initially, flat to lower the next day, with some volatility pulling it below key moving averages). - Amazon (AMZN): Reported after hours on February 5, with mixed results — EPS ~$1.95 (narrow miss vs. ~$1.97 expected), but solid overall. The big negative was a surprise $200B capex forecast for 2026 (well above expectations), tied to AI/cloud buildout. Shares plunged sharply — down ~7–10% in after-hours/extended trading, with Friday moves around -5–8% in some sessions. Recent Tech CAPEX announcements - Amazon (AMZN) — Guided to approximately $200 billion in capex for 2026 (a massive jump from ~$125–131 billion in 2025, with ~80% likely AI-related per analyst commentary). This was the largest single-company figure and a major surprise, contributing heavily to the week's "wild" reactions. - Alphabet (GOOGL/GOOG) — Guided to $175–185 billion in capex for 2026 (roughly double the $91 billion spent in 2025, far above analyst expectations of ~$115–119 billion). Emphasis was on AI compute capacity, servers, data centers, and networking to meet demand for Gemini and cloud services. - Meta Platforms (META) — Guidance from late January (but heavily discussed last week): $115–135 billion for 2026 (up significantly from ~$70–72 billion in 2025, potentially an ~87% increase). - Microsoft (MSFT) — No new full explicit 2026 guidance in early February (fiscal year runs July–June), but recent quarterly run-rate and analyst projections put it around $97–145 billion (with some sources citing ~$105 billion or higher based on Q2 spending trends and signals of continued growth from prior levels of ~$88 billion in FY2025). ------!!!!Combined 2026 capex projected at $635–665 billion (low/high ends) or up to $650–700 billion in some reports — a ~60–74% increase from their collective ~$381 billion in 2025. Market Reaction from all of this.... - Markets were a bit spooked on the Anthropic announcement earlier in the week - software sold off and set a sour mood - Microsoft dumped pretty hard as the amount of spend was higher than anticipated, especially with some slower growth in Azure. - Amazon took a beating on the increased spend they anticipate *(extra by $50B) - BUT: Friday markets rallied as there was realization that the $200B spend by Amazon would seep into the economy and fuel infrastructure spending along with chips, tech etc. Other Earnings of Interest -  Reddit reported fourth-quarter earnings on Thursday in which the social media company beat on the top and bottom lines. - The company said it expects first-quarter sales to come in the range of $595 million to $605 million, which is higher than Wall Street expectations of $577 million. - Reddit also announced a $1 billion share repurchase program. - Reddit gets about $250 million a year from OpenAi and Google to have your data for training their LLMs While we are on the subject - Friday, DJIA hit 50,000 - first time ever! - Up 1,200 point of which approx 350 was from caterpillar and 280 was from Goldman Sachs Hats off to WalMart - Walmart Inc. shares pushed its market capitalization past $1 trillion on Tuesday for the first time ever| - Big transformation over the pst year - Walmart has maintained its appeal to households looking for value, its online offerings are drawing new, wealthier shoppers seeking convenience. Google Bond Offering - Issuing several tranches of bonds, denominated in Stirling - one as long as 100 years - Would you buy that? - The Google parent is set to raise $20 billion from a US dollar bond offering on Monday — more than the $15 billion initially expected — and is also pitching investors on what would be its first ever offerings in Switzerland and the UK. - The latter would include a rare sale of 100-year bonds, the first time a tech company has tried such an offering since the dotcom frenzy of the late 1990s Fat Profits in Dietville - Really interesting sequence of events happening... - Hims launches compounded pill at prices as low as $49 per month - Analysts cite questions on efficacy, legality of pill - Hims' move shifts focus from Novo's strong Wegovy pill launch - Broader obesity market whipsawed as pricing pressure rises THEN.. - Hims and Hers Health shares dive 14% after hours on Friday (Down 25% on Monday) - FDA cites concerns over quality, safety, federal law - The U.S. Food and Drug Administration said on Friday it would take action against telehealth provider Hims & Hers, for its $49 weight-loss pill, including restricting access to the drug's ingredients and referring the company to the Department of Justice for potential violations of federal law. AND.... - Eli Lilly last Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. - The pharmaceutical giant anticipates its 2026 revenue will come in between $80 billion and $83 billion. Analysts expected revenue of $77.62 billion, according to LSEG. - Meanwhile, NOVO had a really bad outlook that took the shares down 13% after the report. Japan Markets Soar - Japanese stocks jumped to a record high Monday, leading gains in the region after Prime Minister Sanae Takaichi won a landmark election victory. - The ruling Liberal Democratic Party captured a two-thirds supermajority in the 465-seat lower house, public broadcaster NHK reported. - Japan's Nikkei 225 jumped past 57,000 for the first time before paring gains to close 3.9% higher at 56,363.94, while the Topix also notched a record high, closing at 3,783.94, up 2.3%. Employment Report? - Government shutdown is forcing them to postpone again (Which is dumb) - Number due this Wednesday - Maybe because of this:U.S. employers announced 108,435 layoffs for the month, up 118% from the same period a year ago and 205% from December 2025. The total marked the highest for any January since 2009. - At the same time, companies announced just 5,306 new hires, also the lowest January since 2009, which is when Challenger, Gray & Christmas began tracking such data. - Also, job openings fell sharply in December to 6.54 million, to their lowest since September 2020. - Available jobs are down by more than 900,000 just since October. - NO! Ai and advancements in tech have noting to do with this! NO NO NO M&A - Texas Instruments Inc. has reached an agreement to buy Silicon Laboratories Inc. for about $7.5 billion, deepening its exposure to several markets for chips. - Silicon Labs investors will receive $231 in cash for each share of the company's common stock and the transaction is expected to close in the first half of 2027. - The transaction still needs to win approval by investors in Silicon Labs and shares of Silicon Labs surged by 51% to $206.48 after the announcement. Inflation - This helps - PepsiCo (PEP.O), opens new tab will cut prices on core brands such as Lay's and Doritos by up to 15% following a consumer backlash against several previous price hikes, the snacks and beverage maker said on Tuesday after it topped fourth-quarter results. Miran - Moving - Federal Reserve Governor Stephen Miran is leaving his post as chair of the Council of Economic Advisers, CNBC has confirmed. - He joined the CEA in January 2025, but had been on leave from that post since last September when he filled the unexpired term of former Fed Governor Adriana Kugler.- He reamins on Fed board No Biggie???? - There are some astonishing cased being reported of Bad AI in the operating room - JNJ's TruDi Navigation System - Since AI was added to the device, the FDA has received unconfirmed reports of at least 100 malfunctions and adverse events. - At least 10 people were injured between late 2021 and November 2025, according to the reports. Most allegedly involved errors in which the TruDi Navigation System misinformed surgeons about the location of their instruments while they were using them inside patients' heads during operations. - Cerebrospinal fluid reportedly leaked from one patient's nose. In another reported case, a surgeon mistakenly punctured the base of a patient's skull. In two other cases, patients each allegedly suffered strokes after a major artery was accidentally injured. Cuba - The main airport has putt out a bulletin that they are out of Jet Fuel - Blackouts and lack of other fuels are creating big problems - No airlines have stopped running at this point, but many will as they cannot refuel - This is a bigger problem for cargo planes (supplies) that may not be able to risk flying to Cuba as they will not be able to get out. Love the Show? Then how about a Donation? ANNOUNCING THE WINNER OF THE THE CLOSEST TO THE PIN CUP 2025 Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt!     FED AND CRYPTO LIMERICKS   See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Confira os destaques de Os Pingos nos Is desta terça-feira (10):A defesa do ex-presidente Jair Bolsonaro (PL) deve apresentar um novo pedido de prisão domiciliar, segundo anúncio feito por Carlos Bolsonaro nas redes sociais. O argumento é baseado em laudos da Polícia Federal e do médico assistente que apontam comorbidades relevantes e riscos elevados à saúde do ex-presidente. O Brasil manteve em 2025 a segunda pior nota de sua série histórica no Índice de Percepção da Corrupção, divulgado pela Transparência Internacional. O país registrou 35 pontos em uma escala de 0 a 100 e ficou na 107ª posição entre 182 nações avaliadas. Apesar da leve alta em relação a 2024, a variação é considerada estatisticamente insignificante, indicando estagnação na percepção sobre corrupção no setor público. Entidades do setor produtivo demonstraram preocupação com a proposta de acabar com a escala de trabalho 6x1, que pode gerar impactos bilionários nos custos das empresas. Representantes da indústria também criticam a condução do debate em Brasília e afirmam não terem sido chamados para discutir o tema. O presidente da Câmara, Hugo Motta, quer votar a medida até maio. Estudo do Instituto de Pesquisa Econômica Aplicada (Ipea) indica que a redução da jornada semanal para 40 horas elevaria o custo médio do trabalho celetista em 7,84%, impacto semelhante a aumentos recorrentes do salário mínimo. Apesar disso, a pesquisa aponta que a maioria dos setores conseguiria absorver a mudança. Hoje, grande parte dos trabalhadores formais ainda cumpre jornadas de 44 horas semanais. O ministro da Fazenda, Fernando Haddad, afirmou que continua conversando com o presidente Lula sobre uma possível candidatura ao governo de São Paulo em 2026. Apesar das pressões políticas, o ministro disse que seguirá ouvindo o presidente antes de tomar uma decisão definitiva sobre a disputa no maior colégio eleitoral do país. O presidente nacional do MDB, Baleia Rossi, reuniu-se com o governador de São Paulo, Tarcísio de Freitas, e afirmou que a conversa reforçou a parceria entre a sigla e o governo paulista. O encontro ocorre enquanto o presidente Lula (PT) tenta atrair o MDB para sua chapa à reeleição, inclusive com a possibilidade de indicar um vice do partido. Nos bastidores, o movimento é visto como sinal de disputa interna sobre o rumo da legenda em 2026. O ex-governador do Rio de Janeiro, Wilson Witzel, anunciou sua pré-candidatura ao governo do estado. Cassado em 2021 após suspeitas de desvios de recursos na saúde durante a pandemia, o político afirma estar mais experiente e preparado para retornar à vida pública. Para disputar as eleições, Witzel busca uma nova sigla de centro-direita. Você confere essas e outras notícias em Os Pingos nos Is.

O programa Meio-Dia em Brasília desta quarta-feira, 11 de fevereiro, fala sobre a representação apresentada pelo partido Novo questionando o desfile da escola de samba Acadêmicos de Niterói que vai homenagear o presidente Lula.Além disso, o jornal também fala sobre o folgão de Carnaval dos deputados federais e sobre um vídeo envolvendo o líder do governo no Congresso, Randolfe Rodrigues (PT-AP), que tem sido ridicularizado nas redes sociais.Meio-Dia em Brasília traz as principais notícias e análises da política nacional direto   de Brasília.     Com apresentação de José Inácio Pilar e Wilson Lima, o programa aborda os temas mais quentes do cenário político e econômico do Brasil.     Com um olhar atento sobre política, notícias e economia, mantém o público bem informado.   Transmissão ao vivo de segunda a sexta-feira às 12h.   Apoie o jornalismo independente. Assine O Antagonista e Crusoé com 10% via Pix ou Google Pay   https://assine.oantagonista.com.br/   Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br 

O Partido Novo protocolou nesta terça-feira (10) uma representação no Tribunal Superior Eleitoral (TSE) por propaganda eleitoral antecipada contra o presidente Luiz Inácio Lula da Silva, o PT e a escola de samba Acadêmicos de Niterói.A ação questiona o enredo "Do alto do mulungu surge a esperança: Lula, o operário do Brasil", que homenageará o mandatário na Sapucaí. A oposição argumenta que o desfile utiliza elementos típicos de campanha, como o número 13 e jingles históricos, o que comprometeria a isonomia do processo eleitoral de 2026.Meio-Dia em Brasília traz as principais notícias e análises da política nacional direto   de Brasília.     Com apresentação de José Inácio Pilar e Wilson Lima, o programa aborda os temas mais quentes do cenário político e econômico do Brasil.     Com um olhar atento sobre política, notícias e economia, mantém o público bem informado.   Transmissão ao vivo de segunda a sexta-feira às 12h.   Apoie o jornalismo independente. Assine O Antagonista e Crusoé com 10% via Pix ou Google Pay   https://assine.oantagonista.com.br/   Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br 

O recé-eleito Presidente Seguro (antes, António Jé) vai iniciar uma nova etapa da sua vida. Que desafios o esperam a nível internacional? Quem serão os seus amigos? E os seus inimigos?

This Day in Legal History: Nelson Mandela ReleasedOn February 11, 1990, Nelson Mandela was released from Victor Verster Prison in South Africa after 27 years of incarceration, marking a seismic shift in the country's legal and political landscape. Mandela's release followed a period of secret negotiations between the apartheid government and the African National Congress (ANC), and it signaled the beginning of the end of apartheid—a system of institutionalized racial segregation and oppression upheld by law. His imprisonment had become a global symbol of the fight against racial injustice and was frequently challenged by international human rights organizations and legal scholars as a violation of fundamental human rights.Mandela had been convicted in 1964 of sabotage and other charges under South Africa's Suppression of Communism Act, following the infamous Rivonia Trial. He was sentenced to life imprisonment, spending much of his sentence on Robben Island under harsh conditions. Over the decades, growing international sanctions and internal unrest made apartheid increasingly untenable.Then-President F.W. de Klerk's government began rolling back apartheid legislation in the late 1980s, and on February 2, 1990, de Klerk announced the unbanning of the ANC and his intention to release Mandela. Just nine days later, Mandela walked free, delivering a speech in Cape Town that emphasized reconciliation, peace, and the continuation of the struggle for full democratic rights.Mandela's release was not just a political milestone—it was a legal one, too. It reflected a move away from laws based on racial supremacy and toward a constitutional order grounded in human rights. This transformation would culminate in South Africa's 1996 Constitution, often lauded for its rights-based framework and independent judiciary.The Trump administration's plan to repeal the EPA's 2009 endangerment finding—the scientific basis for regulating greenhouse gases under the Clean Air Act—could reignite legal efforts to hold polluters accountable through public nuisance lawsuits. That finding enabled the EPA to regulate emissions from vehicles and power plants, but its reversal removes the legal framework that had previously shielded companies from such claims under a 2011 Supreme Court ruling. In that decision, the Court held that the EPA's authority under the Clean Air Act displaced common-law nuisance suits against emitters. Without that EPA oversight, legal scholars believe plaintiffs may now argue that the courts are once again an appropriate venue for these claims.Public nuisance lawsuits, typically filed by states or municipalities, seek to hold companies accountable for harms caused to community health and safety. These cases have been historically difficult to win due to challenges in proving direct causation, but experts say the new regulatory gap could encourage a wave of litigation. Industry groups like the Edison Electric Institute have warned that repealing the endangerment finding could expose utilities to costly legal battles. While federal courts had largely blocked such claims, state courts have shown more openness, and the shift in federal policy may strengthen these legal efforts. Environmental advocates may now have renewed leverage to push power companies and other emitters into court.Trump's repeal of climate rule opens a ‘new front' for litigation | ReutersAttorney General Pam Bondi is scheduled to testify before the House Judiciary Committee this week amid intensifying legal scrutiny over the Justice Department's management of the Jeffrey Epstein files. Lawmakers are expected to question Bondi about what they view as excessive redactions and the DOJ's withholding of key documents, actions that may conflict with a bipartisan federal law passed in 2025 mandating the broad release of Epstein-related materials. Legal analysts suggest the DOJ's reliance on legal privileges—such as investigatory and deliberative process exemptions—to justify redactions could face stiff challenges in court or through congressional oversight powers.The situation raises constitutional tensions between legislative oversight and executive privilege, particularly as the House panel, now under Republican control, examines whether the DOJ is shielding politically sensitive information. Some members of Congress have accused the Department of undermining transparency and potentially violating the statutory intent of the Epstein Disclosure Act, which narrowed the DOJ's discretion in withholding records tied to convicted sex offenders or deceased suspects like Epstein.Bondi's DOJ has been accused of prioritizing partisan enforcement over institutional neutrality, illustrated by failed prosecutions of Trump critics and an aggressive posture on immigration and protest-related cases. The sidelining of the DOJ's civil rights division and the refusal to investigate federal shootings has further fueled concerns over selective enforcement and erosion of prosecutorial independence. Bondi's testimony will serve as a key moment to defend the Department's use of legal redactions and its broader approach to politically charged prosecutions.Bondi to face questions on Epstein files in House testimony | ReutersInstagram chief Adam Mosseri is set to testify in a Los Angeles courtroom this week in a groundbreaking lawsuit that could reshape how U.S. law approaches the intersection of product design and youth mental health. The case centers on a 20-year-old plaintiff who alleges she became addicted to Instagram as a child due to its deliberately addictive interface—particularly the “endless scroll” feature that loads content continuously to hold user attention. Her lawyers argue that Instagram's design choices amount to a form of negligent product engineering that failed to account for known risks to children.This case raises novel legal questions: Can user interface (UI) design be treated as a defective product under tort law? Can tech companies be held liable not just for content but for the architecture of the platforms themselves? If the court accepts these arguments, it could establish precedent for treating addictive design as a public health harm similar to tobacco or opioid marketing practices.Mosseri is expected to face questioning over internal documents that, according to the plaintiff, show Meta was aware of the app's mental health impact on vulnerable teens. Meta counters that these documents reflect efforts to mitigate harm, not evidence of negligence. Still, the case may test the limits of Section 230 immunity, as it focuses not on third-party content, but the platform's own design—potentially sidestepping the traditional legal shield for tech companies.Hundreds of similar cases are pending, and this trial may serve as a bellwether for litigation nationwide. International developments, including Australia's ban on social media for children under 16, suggest this is a growing legal frontier.Instagram's leader to testify in court on app design, youth mental health | ReutersNovo Nordisk's recent patent infringement lawsuit against Hims & Hers marks a pivotal legal development in the pharmaceutical industry's battle with telehealth providers distributing compounded drugs. The suit, filed in Delaware federal court, targets Hims' sales of compounded semaglutide—the active ingredient in Wegovy and Ozempic—claiming these formulations infringe Novo's patents. While compounding is allowed under certain FDA exemptions, those exemptions do not shield pharmacies or telehealth platforms from patent liability. This case challenges the assumption that FDA compliance protects against infringement claims, exposing a gray area where regulatory and intellectual property regimes collide.Historically, brand-name drugmakers focused on trademark challenges over how compounded drugs were marketed. Novo's move into patent litigation signals a strategic escalation: it's not about branding anymore—it's about the act of making and selling the compound itself. Experts highlight that this is likely the first time a brand drug company has pursued patent claims directly against a compounding pharmacy or telehealth distributor, suggesting the industry now sees these entities as substantial commercial threats.The case also underscores a novel enforcement strategy: suing the telehealth platform facilitating sales rather than the dispersed network of compounding pharmacies, streamlining legal action and potentially setting precedent for centralized liability. Hims, already under regulatory scrutiny, had just halted plans to sell compounded semaglutide pills but remains a target due to its involvement in injectable forms.The outcome of this case may clarify how FDA-sanctioned compounding intersects with patent protections and could define the boundaries for how far telehealth companies can go in offering customized versions of patented drugs.Novo's GLP-1 Patent Suit Against Hims Takes Aim at Compounding This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

No Desculpa Alguma Coisa desta semana, Tati Bernardi recebe a chef Bel Coelho.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: T1D in the Olympics & Superbowl, Trump RX goes live, Ozempic pill available soon, tech updates from Medtronic, Beta Bionics, Eversense 365 and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: We are just over one week from our first Moms' Night Out event of the year. While the plans are all set – the speakers, the vendors, the raffles and the fun is ready to go, it's always amazing how many people hear of these event last minute. That's fine, they're welcome! But if you're thinking of attending a future event – registration is open for We're going to Nashville next March 6-7 and Detroit in September – no need to wait. And we've got Club 1921 events for health care professionals and patient leaders in 6 cities this year! All the info is over at diabetes-connetionss.com events/   Okay.. our top story this week: XX Gotta be a quick shout out to some incredible T1D athletes – we had TWO in the super bowl this past weekend – Chad Muma of the New England Patriots and Logan Brown of the Seattle Seahawks AND there are at least two athletes with type 1 competing at the Winter Olympics. Hannah Schmidt competes in ski cross for Canada – she was diagnosed with Type 1 diabetes at age 12 years old.  Anna FarnSchadt Fernstäd a Czech skeleton racer diagnosed in 2022 after she'd already been to several Olympics. We wish them all the best!   https://english.radio.cz/skeleton-racer-anna-fernstadtova-overcoming-adversity-headfirst-down-ice-8876699 XX The government website TrumpRx.gov is live..  the website does not sell prescription drugs. Instead, it allows people to look up their drugs and then navigate to buy them elsewhere, either from a major drug company or a pharmacy. The 43 drugs listed on the site have prices ranging from $3 to over $5,500. TrumpRx does include warnings that the site may not be the best option to save money on prescriptions. Each product page advises: "If you have insurance, check your co-pay first — it may be even lower." For now, the website says its prices are for people paying with their own money, rather than going through insurance. The only insulin listed right now is Lilly's insulin lispro – and it's the same price as you'd find through Illy's insulin value program. I looked up diabetes meds.. For example, if you have an insurance co-pay of $25 a month for Farxiga, a drug often used for diabetes, you would be paying $182 on TrumpRx. As you can imagine, though ,this is complicated and as with most of our healthcare system, it may be good in some cases and not much help in other.  I'd suggest calling your local pharmacist or checking with your human resource dept. https://www.nytimes.com/2026/02/06/health/trumprx-prescription-drug-prices-consumers.html XX Novo Nordisk will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year. The company said the U.S. Food and Drug Administration has approved Ozempic tablets in three different doses. Novo says The new Ozempic name is intended to help patients and health care professionals more easily recognize the available treatment options for type 2 diabetes Semaglutide tablets have been available under the brand name Rybelsus Ruh BELL sis for diabetes since 2019 but with different dosing. The pill is also approved to reduce the risk of certain cardiovascular conditions in adults with type 2 diabetes who are at high risk for these events. The FDA had approved the new doses based on a bioequivalence study and the clinical trial data for Rybelsus, Novo said. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-launch-ozempic-pill-diabetes-second-quarter-this-year-2026-02-04/ XX https://www.contemporarypediatrics.com/view/early-screening-for-type-1-diabetes-found-effective-in-children XX Possible new way to identify and track the progress of type 1 diabetes before clinical onset. A recent study published in Science Advances described the application of subcutaneous microporous scaffolds. These are inserted and have been shown to  identify changes in cancer, multiple sclerosis, and T1D by capturing changes of immune cells over the course of a disease. This is a proof of concept study in mice.. so very early days. https://www.news-medical.net/news/20260204/Implantable-immune-scaffold-predicts-type-1-diabetes-weeks-before-symptoms.aspx XX A large global genetics study shows that many key drivers of Type 2 diabetes operate outside the bloodstream. In a major international project led in part by the University of Massachusetts Amherst and Helmholtz Munich in Germany, researchers linked hundreds of genes and proteins to the disease. The work, published in Nature Metabolism, points to a key challenge in diabetes research: the biology behind rising blood sugar does not play out the same way in every part of the body. It also shows why including people from many backgrounds matters, since genetic clues that stand out in one population may be faint or invisible in another. Huge study, 2.5 million people worldwide comparing patterns across seven tissues tied to diabetes and four global ancestry groups, then asked a simple question: what do you miss if you only measure blood? Across the seven tissues, the researchers found causal evidence pointing to 676 genes. Yet overlap with blood was limited: only 18% of genes with a causal effect in a primary diabetes tissue, such as the pancreas, showed a matching signal in blood. At the same time, 85% of genetic effects observed in diabetes-relevant tissues were completely absent from blood-based analyses. The findings lay out a roadmap for future research aimed at understanding the biological pathways underlying Type 2 diabetes and developing more effective treatments. https://scitechdaily.com/massive-global-study-rewrites-the-biology-of-type-2-diabetes/ XX Express Scripts settled the U.S. Federal Trade Commission's claims its insulin pricing practices violated antitrust and consumer protection laws, and agreed to changes aimed at lowering costs for patients, insurers and small pharmacies The settlement, first reported by Reuters, fits with that goal, and allows the FTC to pare down a case brought by the former Biden administration against Cigna's Express Scripts, UnitedHealth Group Inc's (UNH.N), Optum unit and CVS Health Corp's (CVS.N), CVS Caremark. The case against Optum and Caremark is ongoing. Pharmacy benefit managers, which set how drugs are covered by health insurance, have faced a decade of scrutiny from regulators and lawmakers over pricing practices. While the industry has already made reforms, the settlement gives the FTC power to enforce broader changes at Express Scripts. The 10-year agreement restricts Express Scripts' ability to engage in practices critics say contribute to high costs, like pocketing rebate payments from drugmakers based on the list price of drugs. The FTC estimates the agreement could save patients as much as $7 billion over a decade. https://www.reuters.com/world/cigna-settles-ftc-insulin-case-commits-overhauling-drug-pricing-2026-02-04/ XX Audio? Congress has passed bipartisan legislation to extend and strengthen the Special Diabetes Program (SDP), a cornerstone of Federal investment in type 1 diabetes (T1D) research. The President signed the legislation and it is now law. Extends the SDP through December 31, 2026, and increases funding from $160 million to $200 million annually. Strengthens overall funding for the National Institutes of Health (NIH) by $415 million. Increases diabetes research funding at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) by $10 million. Created by Congress and administered by the NIH, the SDP has contributed nearly $3.6 billion to T1D research and has played a role in nearly every major breakthrough in the field. A recent study conducted by Avalere Health shows that of the nearly 3.6 billion invested into the SDP by Congress since the establishment of the program, the Federal Government has realized $50 billion in healthcare savings through improved health outcomes from the use of SDP driven therapies and devices https://www.breakthrought1d.org/news-and-updates/congress-passes-bipartisan-extension-of-the-special-diabetes-program-securing-critical-t1d-research-funding/ XX Dexcom is rolling out what they're calling AI-enabled enhancements to Stelo, further transforming how users track and understand their glucose health. Expanded Smart Food Logging including a comprehensive nutrition database of more than 1M meals that provides a breakdown of calories, carbohydrates, protein, fat, dietary fibers, and more. More ways to meal track including text search, barcode scanning or taking a photo of the meal, creating a seamless and intuitive meal tracking solution. A redesigned Daily Insights feature which will introduce a new interface with more personalized recommendations. The newest features will launch nationwide in the coming weeks.  XX Beta Bionics has received a warning letter from the Food and Drug Administration following an inspection last year, the company disclosed on Friday. The diabetes technology company said in a securities filing that the warning letter concerns non-conformities with the company's quality management system, medical device reporting, and correction and removals. The warning letter has not yet been posted by the FDA.   The company said in the filing that it has already taken actions to improve the processes described in the warning letter, and it is working on a written response to the FDA.   The firm does not expect the warning letter to affect the planned launch of a new insulin patch pump by the end of 2027. Beta Bionics unveiled a prototype of the device, called Mint, last year at the American Diabetes Association's Scientific Sessions. The company also does not expect the warning letter to affect its financial results. https://www.medtechdive.com/news/beta-bionics-receives-fda-warning-letter/811140/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue%3A+2026-02-04+MedTech+Dive+%5Bissue%3A81423%5D&utm_term=MedTech+Dive&fbclid=IwY2xjawPwhDZleHRuA2FlbQIxMABicmlkETFaUUcyYmNQWldjZ2xudElic3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHouF8M3IstTyslPRgeHWUWVVdOAGOtzPWt_yNFcj9eYruqSPz3e86Iwcbpt8_aem_7q4D97vJVjHKfEwvoyUpgw XX Sequel Med Tech is reviewing co-founder Dean Kamen's ties to Jeffrey Epstein after recently released documents revealed new details about the longstanding relationship between the two men. The documents show that Kamen visited Epstein's island, and remained in contact with him for years after Epstein was convicted of sex crimes involving minors. Kamen has not been accused of any wrongdoing. In a statement, Sequel Med Tech said the Manchester-based company is aware of the documents pertaining to Kamen and – quote - "Sequel's Board of Directors has unanimously decided to engage an external law firm to review these disclosures and provide recommendations aligned with our mission to serve people living with diabetes," Kamen has not issued a statement regarding his reported connection to Epstein.   https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.nbcboston.com/news/local/nh-inventor-placed-on-leave-after-epstein-messages-surface-report-says/3888569/ XX Abbot reports 860 serious injuries linked to the recall of some of its glucose monitoring sensors. We told you about this recall late last year, these numbers are an FDA update.     Abbott said the sensors can provide incorrect glucose readings over extended periods, which could lead to users making dangerous treatment decisions, including eating excessive carbohydrates along with skipping or delaying insulin doses, potentially leading to serious health risks. The company said it has identified and resolved the cause of the issue, which relates to one production line among several that make Libre 3 and Libre 3 Plus sensors.   https://www.reuters.com/business/healthcare-pharmaceuticals/abbott-recalls-glucose-sensors-after-seven-deaths-linked-faulty-readings-2026-02-04/ XX Updates from Medtronic & Senseonics – and a first from Nick Jonas.. right after this..   I'm excited to share that the FDA has cleared the MiniMed 780G system with the Instinct sensor, made by Abbott, for people with type 2 diabetes.  Medicare has also now approved coverage for the Instinct sensor for use with the MiniMed 780G system. This clearance and expanded coverage mean more people will have access to pairing our most advanced automated insulin delivery technology with the Instinct sensor, that offers a smaller, 15-day sensor experience.  They're also launching the MiniMed 780G system Pump Evaluation Program.  This program gives individuals living with diabetes the ability to try the full MiniMed 780G system at no cost for 30 days.† This includes the pump, the sensor of their choice, one month of infusion sets and reservoirs, everything but the insulin. They'll contact your doctor for you to get a prescription and get the process rolling. https://www.medtronicdiabetes.com/pump-evaluation-program XX Senseonics announced today that its Eversense 365 continuous glucose monitor (CGM) system received CE mark approval – that's European clearance.  This comes on the heels of the launch of Eversense 365 with Sequel Med Tech's twiist pump, marking the first pump integration for the CGM. Senseonics plans to launch Eversense 365 in Germany, Italy, Spain and Sweden in the coming months. Meanwhile, Senseonics continues to work toward an FDA investigational device exemption (IDE) submission for its next-generation Gemini transmitter-less CGM by the end of this year. https://www.drugdeliverybusiness.com/senseonics-ce-mark-eversense-365-cgm/ XX A huge shout out to Dr. Emily Blum, who just accomplished riding 100 miles in Antarctica for Breakthrough T1D! Despite having no direct connection to Type 1 Diabetes, Emily has been riding and fundraising for BreakthroughT1D for 10 years now. She is an integral part of the Georgia Ride team, training and riding many miles, and most importantly has raised tens of thousands of dollars to support the cause of ridding the world of T1D. She is surgeon and deeply involved with medical innovation, with an incredibly busy schedule, but jumped at the chance to take on the challenge of riding a century on every continent. Having already completed North America, Europe, Australia, Asia, and now Antarctica, only Africa and South America remain. Emily rides on and continues to be an inspiration to everyone who meets her. XX   https://diabetes-connections.com/t1d-connection-and-people-magazine-elise-zach-share-their-story/ XX Nick Jonas's becomes the first artist ever to wear a CGM on an album cover - new upcoming solo album Sunday Best, releasing Feb. 6.  The release says: This marks a powerful step forward in normalizing diabetes and raising awareness for the condition on a global scale. This moment adds to the growing visibility of diabetes in pop culture, alongside milestones like a Type 1 diabetes Barbie and Pixar characters wearing diabetes technology.

Gotovo 99 posto Australaca kojima je dijagnosticiran rak imaju troškove koje moraju sami platiti, čak i kada koriste javni zdravstveni sistem. To je šokantan nalaz najnovije nacionalne ankete organizacije Cancer Council Australia, koja sugeriše da finansijsko opterećenje proizlazi i iz direktnih medicinskih troškova i iz indirektnih troškova u svakoj fazi borbe s rakom. Naročito su pogođeni pacijenti iz regionalnih i ruralnih područja.

As ondas de calor estão cada vez mais frequentes no Brasil e isso já mudou a forma como a gente vive, trabalha e consome energia. No novo episódio do Podcast Canaltech, a repórter Elisa Fontes conversa com João Aureliano, conselheiro da ABRAVA e especialista em engenharia de climatização, para entender como a tecnologia dos aparelhos evoluiu, por que o mercado está crescendo tanto e o que realmente faz diferença na hora de economizar na conta de luz. Falamos sobre ar-condicionado inverter, sensores inteligentes, automação, erros comuns no uso, impactos no consumo de energia e o que esperar da próxima geração de eletrodomésticos. Você também vai conferir: WhatsApp prepara algo que muita gente estava esperando, aposta ousada da Xiaomi está chamando atenção no mercado e mudança no YouTube Music pode pegar muita gente de surpresa. Este podcast foi roteirizado e apresentado por Fernada Santos e contou com reportagens de João Melo, Danielle Cassita e Bruno de Blasi, sob coordenação de Anaísa Catucci. A trilha sonora é de Guilherme Zomer, a edição de Natália Improta e a arte da capa é de Erick Teixeira.See omnystudio.com/listener for privacy information.

São quatro da manhã e meu corpo obedece à chamada da minha mente como um médico atende uma chamada de emergência. Levanto para ir ao banheiro, me enganando a ponto de acreditar que estou desperta apenas por necessidades fisiológicas. Evito acender a luz para que o corpo não ache que é dia, esquecendo que é minha mente que está no comando e, para ela, está na hora de despertar e ruminar.Deito a cabeça, tento encontrar algum conforto e tudo que encontro são pensamentos repetitivos: Por que eu aceitei? Por que eu não disse como aquilo me fazia sentir? Como essa pessoa teve coragem de me perguntar isso? Como vou lidar com a culpa das consequências de ter dito sim enquanto eu queria dizer não? A culpa é um estado feito para oprimir, pra nos manter sob controle. E eu me sinto totalmente controlada. Eu sou a Marcela Ceribelli. Esse é o primeiro episódio de Fissuras, um novo quadro do Bom Dia, Obvious em que eu pego aquilo que me persegue — um livro, uma música, uma cena — e tento transformar em linguagem antes que vire sintoma. A fissura de hoje é: seria a ruminação o custo corporal dos nossos consentimentos vazios?Espero que as minhas fissuras se deem bem com as suas.⁠⁠Para conteúdos exclusivos do Bom dia, Obvious, assine a newsletter da Obvious⁠⁠⁠⁠⁠⁠⁠⁠⁠Nos acompanhe também: Marcela Ceribelli no Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@marcelaceribelli⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram da Obvious: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@obvious.cc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok da Obvious: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@obvious.cc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chapadinhas de Endorfina: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@chapadinhasdeendorfina⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ouça também, outros podcasts da Obvious:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Podcast Chapadinhas de Endorfina.doc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Podcast Academia do Prazer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Livros da Marcela Ceribelli:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sintomas — e o que mais aprendi quando o amor me decepcionou⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Aurora: O despertar da mulher exausta⁠⁠⁠⁠⁠⁠⁠Livros da Valeska Zanello: clique aquiOuça também:Novo álbum da Lily Alen: West End Girl

Audio roundup of selected biopharma industry content from Scrip over the business week ended February 60, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Merck looks to fill Keytruda's shoes; Novartis aims to push through largest expiry period; Novo warns of steep sales decline; Pfizer bullish on obesity; and Lilly expects orforglipron success. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-JES32O67YRBSLC6UV2JFY5KPBQ/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Confira os destaques de Os Pingos nos Is desta sexta-feira (06):Um laudo médico elaborado por peritos da Polícia Federal aponta que Jair Bolsonaro (PL) possui doenças crônicas, mas tem condições de permanecer preso na Papuda. O relatório deve embasar a decisão do ministro Alexandre de Moraes sobre o pedido de prisão domiciliar apresentado pela defesa do ex-presidente. A Polícia Federal deflagrou a Operação Zona Cinzenta para investigar investimentos da Previdência do Amapá no Banco Master. A ação mira dirigentes do órgão e apura a aplicação de mais de R$ 400 milhões em recursos públicos. O ministro Dias Toffoli determinou o envio de processos relacionados ao Banco Master para a primeira instância da Justiça Federal, ao entender que parte das investigações não envolve autoridades com foro privilegiado. A decisão já impacta casos no Rio de Janeiro e em São Paulo.O presidente do PP, Ciro Nogueira, se reuniu com Lula na Granja do Torto em busca de um acordo político para as eleições no Piauí. A articulação envolve a renovação do mandato de senador e pode redefinir alianças no estado. O ex-deputado federal Eduardo Bolsonaro (PL-SP) cobrou publicamente maior engajamento da direita na pré-candidatura de Flávio Bolsonaro (PL-RJ) à Presidência em 2026. A manifestação reforça a tentativa do grupo de unificar aliados e acelerar articulações políticas para a disputa eleitoral. O ministro Aroldo Cedraz, do Tribunal de Contas da União, decidiu manter o repasse de R$ 1 milhão à escola de samba Acadêmicos de Niterói, mesmo após recomendação contrária da área técnica do tribunal. A controvérsia envolve o samba-enredo em homenagem ao presidente Lula e um pedido do partido Novo que apontava possível desvio de finalidade. O vice-presidente Geraldo Alckmin respondeu às declarações de José Dirceu, que classificou a aliança com Lula como um acordo político. Alckmin agradeceu a confiança do ex-ministro e afirmou que a decisão sobre a próxima chapa presidencial será tomada no momento oportuno. Você confere essas e outras notícias em Os Pingos nos Is.

Market update for Friday February 6, 2026Check out the Public app for incredible investing tools and to support the show (LINK)Follow us on Instagram (@TheRundownDaily) for bonus content and instant reactions.In today's episode:Bitcoin suffers its worst selloff since the FTX collapse as crypto markets melt downAmazon shares slide after the company unveils a massive $200B AI capex planNvidia delays new gaming chips because of memory shortageRoblox pops after blowout bookings growth and strong user momentumHims slides after warning from FDA and Novo about copycat pill A look at the business behind the 2026 Winter Olympics kicking off in Italy

O Café com Videogames é nosso podcast sobre as novidades do mundo dos videogames, gravado segunda feira de manhã. Nesse episódio, falamos sobre as nossas impressões de Mio: Memories in Orbit e Cairn, sobre o anúncio de um novo Huntdown, datas de lançamento e mais! Apoie o projeto e permita que ele continue: https://apoia.se/nautilus Encontre-nos também nas redes sociais: Instagram: / nautiluslink Bluesky / nautiluslink Lives: / nautiluslink Podcasts: / nautiluslink Discord: https://bit.ly/DiscordNautilus

Link promocional para audiência do Narrativas. Beway Idiomas:   https://mkt.bewayidiomas.com.br/?a=16517723  Narrativas analisa os acontecimentos do Brasil e do mundo sob diferentes perspectivas.     Com apresentação de #MadeleineLacsko, o programa desmonta discursos, expõe fake news e discute os impactos das narrativas na sociedade.     Abordando temas como geopolítica, comunicação e mídia, traz uma visão aprofundada   e esclarecedora sobre o mundo atual.     Ao vivo de segunda a sexta-feira às 17h.   Apoie o jornalismo Vigilante: 10% de desconto para audiência do Narrativas  https://bit.ly/narrativasoa   Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br 

Et tidligt fremlagt regnskab fra danskernes tidligere darling, Novo Nordisk, sendte aktien lige lukt i hullet på børsen i USA tirsdag. Men var det berettiget eller en overreaktion på et regnskab, som muligvis viser kortsigtede udfordringer, men også bliver tillagt potentiale på langt sigt fra flere analytikere? Millionærklubben tjekker tallene i studiet sammen med aktiechef i HC Andersen Capital, Michael Friis Jørgensen, og direktør i og stifter af Global Health Invest, Claus Johansen. Med på en telefon er også CEO i D/S Norden, Jan Rindbo, om dagens aktuelle regnskabstal, og senior aktieanalytiker i Jyske Bank, Haider Anjum, giver sit besyv med om DSV. Vært: Bodil Johanne GantzelSee omnystudio.com/listener for privacy information.

Confira os destaques de Os Pingos nos Is desta segunda-feira (02):O Congresso Nacional retomou os trabalhos legislativos em 2026 com uma abertura protocolar e um ano encurtado pelas eleições. Entre as prioridades estão o debate sobre o fim da escala 6x1, a PEC da Segurança Pública, a regulamentação da inteligência artificial e pedidos de novas CPIs, incluindo o caso Banco Master. Na abertura do ano judiciário de 2026, o presidente do STF, Edson Fachin, voltou a defender a criação de um código de conduta para os ministros. O discurso teve tom firme, com recados sobre limites, transparência e legitimidade da Corte.A Justiça de São Paulo condenou Pablo Marçal a pagar R$ 100 mil ao deputado Guilherme Boulos por disseminação de informações falsas durante a disputa pela Prefeitura da capital em 2024. Ainda cabe recurso da decisão. O deputado Rodrigo Rollemberg protocolou pedido de CPI para investigar o caso Banco Master, com 201 assinaturas na Câmara. A comissão pretende apurar operações bilionárias envolvendo títulos sem lastro e o uso de recursos públicos do BRB. O senador Flávio Bolsonaro (PL-RJ) avalia lançar o deputado federal Nikolas Ferreira ao governo de Minas Gerais em 2026, em articulação com partidos do Centrão. A movimentação depende da posição do governador Romeu Zema, cotado para compor a chapa presidencial, e é vista como estratégica para garantir um palanque forte no segundo maior colégio eleitoral do país. O presidente do Novo, Eduardo Ribeiro, cravou que Romeu Zema não será vice de ninguém em 2026. Segundo ele, o governador de Minas disputará a Presidência e o partido trabalha para consolidar um projeto próprio no primeiro turno. O Republicanos entra em 2026 dividido entre apoiar a pré-candidatura de Flávio Bolsonaro ou preservar a relação com o governo Lula. O impasse reflete disputas regionais e estratégias eleitorais, enquanto o PSD de Gilberto Kassab libera palanques nos estados e mira ampliar sua bancada no Congresso. Você confere essas e outras notícias em Os Pingos nos Is.

Confira os destaques do Jornal da Manhã desta terça-feira (03): A Justiça de São Paulo condenou Pablo Marçal a pagar uma indenização de R$ 100 mil a Guilherme Boulos (PSOL-SP) por danos morais. A decisão foi motivada pela divulgação de fake news associando Boulos ao uso de cocaína durante a campanha para a Prefeitura de São Paulo em 2024. Uma ação de inteligência da Polícia Civil de São Paulo impediu um possível ataque planejado para esta segunda-feira (02) na Avenida Paulista, na região central da capital. Doze pessoas, com idades entre 15 e 30 anos, foram identificadas e levadas para prestar esclarecimentos após monitoramento do Núcleo de Observação e Análise Digital (Noad). Segundo as investigações, o grupo articulava uma suposta “manifestação” sem pauta definida, com o objetivo de provocar tumulto, e planejava o uso de bombas caseiras e coquetéis molotov, com instruções compartilhadas por meio de redes sociais. O governador de São Paulo, Tarcísio de Freitas (Republicanos), aumentou o pagamento de emendas voluntárias destinadas ao PT em 2025, totalizando mais de R$ 107 milhões, um aumento de 60% em relação ao ano anterior. Com isso, o partido do presidente Lula foi o que mais ampliou o volume de recursos recebidos no período. O PSB, do vice-presidente Geraldo Alckmin, também teve aumento. Em contrapartida, partidos da base aliada do governador, como PL, Republicanos, MDB, PSD e Novo, registraram queda nos repasses, apesar de alguns ainda concentrarem os maiores volumes absolutos. O presidente Luiz Inácio Lula da Silva (PT) afirmou que o combate ao crime organizado será uma das prioridades do governo em 2026 e garantiu que criminosos “pagarão por seus crimes”, independentemente do tamanho de suas contas bancárias ou do patrimônio investido no mercado financeiro. A declaração consta na mensagem presidencial enviada ao Congresso nesta segunda-feira (2). Lula destacou a aprovação de projetos ligados à segurança pública e citou a operação Carbono Oculto. A Rússia retomou nesta terça-feira (03) os ataques contra a infraestrutura de energia da Ucrânia, deixando mais de mil edifícios residenciais sem aquecimento em Kiev. Segundo autoridades ucranianas, os bombardeios ocorrem em meio a temperaturas que se aproximam de 20 graus negativos. O Ministério Público Militar deve enviar ao Superior Tribunal Militar um pedido de expulsão do ex-presidente Jair Bolsonaro e de outros quatro militares de alta patente condenados por envolvimento em um plano de golpe. Caso a representação seja aceita, o STM vai julgar se Bolsonaro, os generais Walter Braga Netto, Augusto Heleno e Paulo Sérgio Nogueira, além do almirante Almir Garnier, são considerados “indignos” e “incompatíveis” para permanecer nas Forças Armadas. O deputado federal Rodrigo Rollemberg (PSB-DF) protocolou nesta segunda-feira (02) o requerimento para a instalação de uma CPI destinada a investigar o Banco Master. O pedido conta com 201 assinaturas, superando o mínimo de 171 exigido, e foca na negociação de R$ 12 bilhões em carteiras de crédito sem lastro adquiridas pelo Banco de Brasília (BRB). O príncipe Laurent da Bélgica, irmão do rei Philippe, admitiu que se encontrou duas vezes com Jeffrey Epstein, após inicialmente negar qualquer contato. A confirmação veio depois da divulgação de documentos pelo Departamento de Justiça dos Estados Unidos que mencionam pessoas ligadas ao financista condenado por crimes sexuais. O Departamento de Segurança Interna dos Estados Unidos, liderado pela secretária Kristi Noem, anunciou que todos os agentes federais em serviço em Minneapolis, incluindo os do Serviço de Imigração e Alfândega (ICE), começarão a usar câmeras corporais imediatamente, em resposta às mortes de dois cidadãos americanos em confrontos com agentes federais que geraram protestos e críticas ao governo. Essas e outras notícias você acompanha no Jornal da Manhã. Learn more about your ad choices. Visit megaphone.fm/adchoices

Big pharma and biotech take the earnings stage this week with reports from Eli Lilly (NYSE: LLNY) and Novo Nordisk (NYSE: NVO) leading the lineup. Will they help the industry once again outperform AI champ NVIDIA (NASDAQ: NVDA), as the industry did in 2025? Karl Thiel, Tom King, and Tim Beyers discuss: - Slow rolling chaos at FDA and its effects on drug approvals. - How to think about risk when investing in biotech. - Earnings predictions for Lilly and Novo as well as a review of results from DNA researcher Twist Bioscience (NASDAQ: TWST). Don't wait! Be sure to get to your local bookstore and pick up a copy of David's Gardner's new book — Rule Breaker Investing: How to Pick the Best Stocks of the Future and Build Lasting Wealth. It's on shelves now; get it before it's gone! Companies discussed: RGNX, LLY, NVO, TWST Host: Tim Beyers Guests: Karl Thiel, Tom King Producer: Anand Chokkavelu Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

O Arsenal goleou o Leeds e aproveitou os tropeços dos rivais para abrir seis pontos de vantagem na liderança da Premier League. Analisamos o impacto do retorno de Gabriel Jesus, que voltou a marcar, e a estranha queda de rendimento do Manchester City nas segundas etapas desta temporada. O episódio ainda traz o giro pelas ligas europeias, com os vacilos de Bayern e Atlético de Madrid, e os movimentos finais da janela de transferências, incluindo a ida de Lookman para o time de Simeone. Na abertura, comentamos a contradição de Gianni Infantino sobre a suspensão da Rússia.SEJA MEMBRO! Seu apoio é fundamental para que o Meiocampo continue existindo e possa fazer mais. Seja membro aqui pelo Youtube! Se você ouve via podcast, clique no link na descrição para ser membro! https://www.youtube.com/channel/UCSKkF7ziXfmfjMxe9uhVyHw/joinNEWSLETTER! Nossa newsletter chega toda sexta aberta a todos com nossos textos sobre o que rolou na semana, e às terças com conteúdo apenas para assinantes: https://newsletter.meiocampo.net/Conheça o canal do Bonsa sobre Football Manager, BonsaFM: https://www.youtube.com/@BonsaFMConheça o canal do Lobo sobre games, o Próxima Fase: https://www.youtube.com/@Proxima_FaseConheça o canal de Leandro Iamin sobre a seleção brasileira, o Sarriá: https://www.youtube.com/@SarriaBrasil

E hoje é dia de MacMagazine no Ar!

Neste episódio, o Infracast recebe Conrado Gama Monteiro e Thiago Priess Valiati, presidente e vice-presidente do Instituto Brasileiro de Direito Regulatório, para uma conversa sobre os principais destaques da agenda regulatória de 2025 e as perspectivas para 2026.A discussão aborda os desafios de independência das agências reguladoras, os impactos políticos e institucionais sobre a regulação e os avanços e entraves em setores de infraestrutura. Ao longo do episódio, os convidados também apresentam a trajetória e a importante atuação do Instituto Brasileiro de Direito Regulatório.Inscreva-se no canal e ouça o Infracast também pelo Spotify.Somos o primeiro podcast brasileiro dedicado exclusivamente aos temas de infraestrutura.#direitoregulatório #infraestrutura #saneamento #políticaspúblicas

A bancada do partido Novo protocolou um requerimento de informação cobrando explicações da Casa Civil sobre um encontro fora da agenda oficial entre o presidente Lula e dirigentes do Banco Master, ocorrido no Palácio do Planalto.Meio-Dia em Brasília traz as principais notícias e análises da política nacional diretode Brasília.Com apresentação de José Inácio Pilar e Wilson Lima, o programa aborda os temas mais quentes do cenário político e econômico do Brasil.Com um olhar atento sobre política, notícias e economia, mantém o público bem informado.Transmissão ao vivo de segunda a sexta-feira às 12h.Apoie o jornalismo Vigilante: 10% de desconto para audiência do Meio-Dia em Brasíliahttps://bit.ly/meiodiaoaSiga O Antagonista no X:https://x.com/o_antagonistaAcompanhe O Antagonista no canal do WhatsApp.Boletins diários, conteúdos exclusivos em vídeo e muito mais.https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344Leia mais em www.oantagonista.com.br | www.crusoe.com.br

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: UK looks at starting universal T1D screening, Dexcom's CEO mentions a new product, bariatric sugery vs GLP medications, FDA approves update to prescribing info for inhaled insulin, miscroplastic and diabetes link studied, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: (Stacey Track) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. We are less than one month from our first MNO of 2026. Please join us in Silver Spring MD Feb 20 and 21. It's going to be amazing. We're going to Nashville next March 6-7 and we're going to have a great event a Club 1921 we just added on Thursday March 5th for health care providers and patient leaders. All the info is over at diabetes-connetionss.com events/ Okay.. our top story this week: XX   All UK children could be offered screening for type 1 diabetes using a simple finger-prick blood test, say researchers who have been running a large study. This is the ELSA study - Early Surveillance for Autoimmune diabetes, a first of its kind UK study. They tested blood samples from 17,931 children aged 3-13 for autoantibodies, markers of type 1 diabetes that can appear years before symptoms. Families of children found to have early-stage type 1 diabetes received tailored education and ongoing support to prepare for the eventual onset of type 1 diabetes symptoms and to ensure insulin therapy can begin promptly when needed, reducing the chances of needing emergency treatment. Those with one autoantibody also received ongoing support and monitoring.   Some families were also offered teplizumab, the first ever immunotherapy for type 1 diabetes, which can delay the need for insulin by around three years in people with early-stage type 1 diabetes. The second phase has launched and will expand screening to all children in the UK aged 2-17 years, with a focus on younger children (2-3 years) and older teenagers (14-17 years). The research team aims to recruit 30,000 additional children across these new age groups. ELSA 2 will assess how screening can be scaled across the NHS and evaluate its cost-effectiveness. https://www.birmingham.ac.uk/news/2026/childhood-type-1-diabetes-screening-is-effective-and-could-prevent-thousands-of-emergency-diagnoses XX At the J.P. Morgan Healthcare Conference Dexcom CEO Jake Leach says they're going to launch a new product outside the US. I'll link up that interview, The full quote: "When you look at the outside the U.S., there are a lot of structures that are tiered. Patients have access to different types of products, so we've got a new one that we want to introduce that will add flexibility there. It's based on the G7 platform, just like Dexcom ONE+, but it has a unique experience that's tailored for a subset of users that, today, don't have access to Dexcom." Your guess is as good as mine, but sounds more like a pricing or ordering issue than a new bit of hardware or software. Dexcom will also bring Stelo to some international markets this year. And plans a new mobile app experience for the wearable biosensor meant for people who don't dose insulin. Leach also says G8 will be much smaller and with more capability. but is a few years away. https://www.drugdeliverybusiness.com/dexcom-ceo-jake-leach-2026-roadmap-jpm/ XX A new international consensus statement provides guidance for the use of diabetes technology during pregnancy for women with type 1 diabetes (T1D), type 2 diabetes (T2D), or gestational diabetes (GD).   Organized by the diaTribe Foundation, the document was based on evidence where available, as well as opinion from an international group of experts in endocrinology, diabetes technology, and obstetrics & gynecology, among others.   This is the first set of recommendations specifically addressing the use of diabetes technology in pregnancy – and we'll link it up. https://www.medscape.com/viewarticle/new-consensus-statement-addresses-diabetes-tech-pregnancy-2026a100020d XX Bariatric surgery beats GLP-1s for type 2 diabetes across income levels. This study was published this month, looking at nearly 300 patients are 4 medical centers. Success here is measured by lower blood glucose levels, higher weight loss (28% vs. 10%), less use of diabetes medications, remission of diabetes to the point of no longer needing to inject insulin, and reduced risk factors for cardiovascular disease.     Bariatric surgery was better than medical therapy across all social backgrounds, they found, and not just in areas of higher deprivation. The ancillary study was smaller, and some of the participants randomized in earlier stages crossed over from medical to surgical treatment, and the reverse. The authors acknowledged and accounted for these limitations, along with the rapid development of more powerful obesity drugs not fully captured in the study. This was a long term study – more than 12 years – and by the end of the study more people were choosing GLP1 medications. One dividing line: If someone hopes to lose 100 pounds, that's more likely with surgery than with medications.  "Ultimately, we need large, long-term, well-designed studies to clarify the best strategy for a given patient." https://www.statnews.com/2026/01/19/diabetes-study-bariatric-surgery-better-than-glp-1s/ XX Researchers at the University of California, Riverside have reported for the first time that a father's exposure to microplastics (MPs) can lead to metabolic problems in his children, including diabetes. This is a mouse study, but it looks at a previously unrecognized way in which environmental pollution may influence the health of future generations. MPs are extremely small plastic fragments, measuring less than 5 millimeters, that form as consumer products and industrial materials break down. Metabolic disorders describe a group of conditions that include elevated blood pressure, high blood sugar, and excess body fat, all of which raise the risk of heart disease and diabetes. The team found that female offspring of male mice exposed to MPs were far more prone to metabolic disorders than offspring of unexposed fathers, even though all offspring received the same high fat diet.     The research team hopes the findings will guide future investigation into how MPs and even smaller nanoplastics affect human development.   https://scitechdaily.com/microplastics-can-rewire-sperm-triggering-diabetes-in-the-next-generation/ XX The FDA has finalized four new recalls for certain lots of Abbott's FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors due to ongoing safety concerns. We told you about this in November when Abbott says some of its continuous glucose monitoring (CGM) sensors were providing incorrect low glucose warnings. Internal testing identified the issue—carbon building up in the sensors during the manufacturing process—and determined that approximately 3 million CGM sensors were affected. The sensors were distributed in the United States, Canada and several European countries.  When Abbott shared that announcement, the FDA was still reviewing the situation. No recalls had yet been finalized. Now, however, the agency has announced four new Class I recalls.   https://cardiovascularbusiness.com/topics/clinical/heart-health/fda-confirms-recalls-abbott-cgm-sensors-new-lawsuit-alleges-company-concealed-information XX   Insulet brings back it's U.S. Pod recycling program, now making it available to all U.S. customers. The Pod recycling program, offered at no cost to customers, enables users to request a recycling kit online. This allows them to return their used Omnipods. Insulet then decontaminates the returned Pods before transporting them to a company specializing in recycling for electronics and medical products. Insulet began recycling pilot programs in Mass and California and are rolling it out nationwide. Insulet also has "Pod takeback" programs outside the U.S. in several international markets. These programs enable customers to request a takeback kit by contacting their local customer support team.   https://www.drugdeliverybusiness.com/insulet-expands-us-pod-recycling-program/ XX Up next a new resource for a population at three times the risk for diabetes, but without a lot of access to health information. I The first diabetes information website primarily in ASL has launched. The site includes GIFs and videos on diabetes management and an ASL glossary of diabetes-related terms. This is from University of Utah Health – Called Deaf Diabetes Can Together. Deaf and hard of hearing people are at three times higher risk for diabetes, but access to health information in ASL is limited. https://healthcare.utah.edu/newsroom/news/2026/01/first-diabetes-information-website-asl-launches XX Novo Nordisk ended all work on cell therapies, including a Type 1 diabetes program, in October – and now has found a buyer. Aspect has acquired rights to the assets and giving Novo an option to reengage for later-stage development and commercialization. Novo is helping bankroll Aspect's development of the assets, investing in the company and providing research funding. The arrangement gives Novo a chance to profit from the programs down the line. Novo is eligible for royalties and milestone payments on future product sales and, having handed the reins to Aspect for now, can expand its role in later-stage development and commercialization. The integration will involve the transfer of capabilities and expertise from Novo sites in Denmark and the U.S. to Aspect's Canadian operations. https://www.fiercebiotech.com/biotech/novo-nordisk-offloads-diabetes-assets-aspect-amid-cell-therapy-retreat XX XX Lucas Escobar has carved a role by proving that healthcare marketing can be culturally resonant, commercially powerful and deeply human. As director and head of U.S. consumer marketing at Insulet, he has redefined how the Omnipod tubeless insulin pump shows up in culture, transforming a medical device into a symbol of identity, inclusion and empowerment.   Under Escobar's leadership, Insulet launched three breakthrough initiatives: Dyasonic: Sound of Strength, a Marvel comic collaboration introducing a superhero who uses Omnipod; The Pod Drop, which turned the sound of a pod change into a celebratory music track; and Omnipod Mango x Pantone, medtech's first color partnership, honoring the vibrancy of the diabetes community. Each blended creativity with purpose while driving results, helping fuel Omnipod's consistent double-digit growth and its position as the most prescribed insulin pump in the U.S.   Living with type 1 diabetes himself, Escobar brings lived experience to his work, using storytelling not just to sell, but to make people feel seen.   Click here to return to the 2026 MM+M 40 Under 40 homepage.   From the January 01, 2026 Issue of MM+M - Medical Marketing and Media https://www.mmm-online.com/40-under-40/40-under-40-lucas-escobar-insulet/ -- FDA approves an update to the prescribing info for Afrezza inhaled insulin. This is a revision to the recommendations for the starting mealtime dosage when patients switch from shots or insulin pumps. This is aimed at healthcare providers - the updated labeling was supported by results from the INHALE-3 trial. The FDA is still considering approval of Afrezza for kids – a decision there expect by summer. https://www.globenewswire.com/news-release/2026/01/26/3225442/29517/en/MannKind-Announces-FDA-Approval-of-Updated-Afrezza-Label-Providing-Starting-Dose-Guidance-when-Switching-from-Multiple-Daily-Injections-MDI-or-Insulin-Pump-Mealtime-Therapy.html   -- UK researchers have developed a calculator to predict whether someone is at risk for type 1 diabetes. They're hoping this helps in screening and in preventing DKA at diagnosis. They used the TEDDY study to create this calculator, which right now is in beta form and only for kids and teens ages 8-18. The current beta form of the calculator asks users to answer questions about four factors necessary to estimate a child's risk of developing type 1 diabetes: age, family history, number of confirmed autoantibodies, and genetic risk score. The calculator has been given regulatory approval as a diagnostic in the U.K., and he's working with a company that's hoping to bring it to the U.S. in the next few months in the form of a home genetic test kit. https://www.healthcentral.com/news/type-1-diabetes/new-calculator-might-help-predict-type-1-diabetes-before-symptoms-appear

Neste episódio, nossos correspondentes falam sobre a primeira derrota do Arsenal em casa na temporada. Time ficou nervoso depois de tomar o empate? E o que explica a queda de rendimento, com apenas 2 pontos nas últimas 3 rodadas? Mas nada, absolutamente nada pode tirar o mérito do Manchester United! Mais uma atuação impecável. Liverpool e Tottenham em crise, Chelsea subindo... e brasileiros brilhando! Estêvão, João Pedro, Igor Jesus e Evanilson marcaram. Ancelotti agradece. 00:00 - Abertura com João mal-humorado 02:00 - Man United vence o Arsenal 04:50 - Arsenal tem elenco pra jogar melhor 09:00 - Nova pipocada? 10:30 - O incrível Manchester United 17:45 - Entrevista Matheus Cunha 20:00 - Manchester City vence e cola no líder 27:00 - As polêmicas da arbitragem 30:30 - Novo vexame do Tottenham 34:50 - Novo técnico? E que sequência difícil… 39:00 - West Ham respira! 40:45 - O Fulham de Harry Wilson 42:00 - Atacantes brasileiros brilhando, quem merece vaga na Copa? 43:30 - Villa segue voando, Newcastle mal 47:05 - Chelsea vence, Estêvão e João Pedro jogando muito 53:10 - Entrevista João Pedro 54:20 - Palace no buraco 58:10 - Bournemouth ganha do Liverpool 01:08:00 - Arsenal ainda favorito? A porcentagem do João… Learn more about your ad choices. Visit podcastchoices.com/adchoices

No Papo Antagonista desta terça-feira, 27, Madeleine Lacsko e Josias Teófilo entrevistaram Eduardo Ribeiro, presidente do Novo. Ele falou sobre os planos de seu partido para 2026 e os desdobramentos do caso Banco Master.Assista:Papo Antagonista é o programa que explica e debate os principais acontecimentos dodia com análises críticas e aprofundadas sobre a política brasileira e seus bastidores.Apresentado por Madeleine Lacsko, o programa traz contexto e opinião sobre os temas mais quentes da atualidade.Com foco em jornalismo, eleições e debate, é um espaço essencial para quem busca informação de qualidade.Ao vivo de segunda a sexta-feira às 18h.Apoie o jornalismo Vigilante: 10% de desconto para audiência do Papo Antagonistahttps://bit.ly/papoantagonistaSiga O Antagonista no X:https://x.com/o_antagonistaAcompanhe O Antagonista no canal do WhatsApp.Boletins diários, conteúdos exclusivos em vídeo e muito mais.https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344Leia mais em www.oantagonista.com.br | www.crusoe.com.br

Prīncipēs probātī atque improbātī Novo annō ineunte, doctī hominēs populāris opīniōnis metiendī perītī referunt quī summī magistrātūs ā suīs cīvibus probentur et quī improbentur. Sōlī, quī ā māiōre parte suōrum probantur, sunt Narendra Mōdī Indus, Sanāē Takaīchī Iāpō, Lee Jae-Myung Corēānus Merīdiōnālis, et Javier Milei Argentīnus. Ā duābus quīntīs partibus suōrum probantur Donaldus Trump Americānus, Lula da Silva Brasiliānus, Geōrgia Melōnī Ītala. Nōn nisi ā tertiā parte suōrum probantur Frederīcus Merz Germānus, Recep Tayyip Erdogan Turca, Petrus Sanchez Hispānus. Maximē autem omnium improbantur Keir Starmer Britannus et Emmanuēl Macron Gallus. Glīscit rēs Americāna Ab Iūliō mēnse usque per Septembrem annōna tōtīus reīpūblicae quattuor partibus centēsimīs crēvit, quod incrēmentum tam cīvium spem quam doctōrum hominum exspectātiōnem superāvit. Scelera adeō pauciōra quam priōre annō patrantur, ut numerus raedārum hōc annō sublātārum quartā parte sit dēminūtus, et quīntā parte numerus dēminūtus sit interfectōrum. Pretia sortium in forō bursālī altiōra stant quam umquam anteā. Nigeria Diē Nātīvitātis, praeses Americānus nuntiāvit sē fēlīcem diem nātālem Christī Mahometānīs terrōristīs exoptāre, quī in Nigeriā stragem Christiānōrum fēcissent; nam eōdem diē, paulō ante praesidis nūntium, mīlitēs Americānī stragem eōrundem terrōristārum fēcerant. Petrus autem Hegseth, Americānus minister bellī, grātiās ēgit Nigeriānīs magistrātibus, quī permīsissent ut impetus fīeret. Ex eō tempore pergunt Nigeriānī contrā terroristās Mahometānōs pugnāre. Venetiola Tertiō diē mēnsis Iānuāriī, Nīcolāus Madūrō, illēgitimus tyrannus quī rempūblicam Venetiolānōrum ēverserat et cum Irāniānīs aliīsque mōliēbātur rempūblicam Americānam subvertere, in dīciōnem Americānōrum redactus est, ut reus fīeret. Incursiō, quā mīlitēs Americānī tyrannum cēpērunt, intrā paucās hōrās est absolūta, et omnēs Americānī reductī sunt integrī et incolumēs, quamquam triginta et duo Cūbānī, satellitēs tyrannī, sunt interfectī. Michāēl Diaz-Canel, quī hāc hebdomade tyrannus pergit esse Cūbānōrum, “Patria aut mors!” clāmāvit, et “Vincēmus.” Dīxit autem praeses Americānus aliīs novi orbis terrārum dūcibus principibusque cavendum esse, nē id, quod Madūrō accidisset, dēnuō alicui accideret alterī. Claudiae Scheinbaum, praesidī Mexicānōrum, posteā vīsum est triginta et septem narcoterroristās in dīciōnem Americānōrum reddere, quōs illī petīverant. Ex eō tempore Americānī nautae etiam coepērunt nāvēs petroleāriās capere, quibus interdictum petroleum vehēbātur ut lucrum variīs tyrannīs redderētur. Unam nāvem, ōlim “Bellam” deinde “Marinēram” nōmine, prope Islandiam Americānī intercēpērunt coram nāve subaquāneā Russicā, quæ tamen Americānīs nōn obstitit. Quinque nāvēs captae sunt, vidēlicet Skipper, Centuries, Marinera, Sophia, Olina sīve Minerva M. Cūba Praeses Americānus monuit nec petroleum nec pecūniam ā Venetiolā ad tyrannidem in Cūbā īnsulā sustinendam lātum īrī; melius fore Cūbānīs negōtium cum Americānīs agere dē suīs rēbus futūrīs. Novī enim magistrātūs Ventiolanī nunc cum Americānīs agunt, ut Americānī petroleum Venetiolānum emant, cūius lucrum ad Venetiolam restaurandam nōn sine moderātiōne Americānā ērogētur. Cūbāna autem dominātiō, quae sexāginta sex annōs populum nōn solum suum opprimit sed etiam Ventiolānum oppressit, et quae strenuē mōlītur rempūblicam Americānam subvertere, nihil petroleī accipiet. Sȳria Hōc mēnse Americānī ūndecimum impetum in Chalifātum Islāmicum lēge tāliōnis fēcērunt, postquam priōre mēnse trēs Ameriānī sunt ab ūnō terroristā interfectī. Petrus Hegseth, minister bellī, “Numquam,” inquit, “oblīvīscēmur, neque īra nostra umquam resīdet.” Magistrātūs Syriānī, quī in hāc rē cum Americānīs stant, quinque terroristās comprehendērunt. Vietnamia Tō Lam, secretārius generālis factiōnis quae communista verbōtenus dīcitur et summus magistrātus Vietnamiēnsium, quinque annōs perget clavum reī pūblicae tractāre. Lam, quī abhinc duōbus annīs coepit magistrātum exercēre, negōtiātōrēs mercātōrēsque, id est prīvātam prōvinciam reī oeconomicae, adeō fovet dum pūblica ministeria restringit, ut Vietnamia magnōpere dītēscat. Iāpōnia Sanāē Takaīchī, ministra prīmāria Iāpōnum, īnferiōrem cameram senātōriam hodiē dissolvit et comitia octāvō diē mēnsis Februāriī habenda indīxit. Quō audītō senātōrēs “Banzae” ex mōre clāmāvērunt. Takaīchī, prīma fēmina dux facta Iāpōnum, ā septēnīs ē dēnīs cīvibus laudātur, itaque spērat fore ut possit comitiīs habendīs factiōnis suae auctōritātem rōborāre. Ītalia In Ītaliā pūblicī accūsātōrēs nūntiāvērunt Batāvōrum auxiliō novem hominēs esse comprehēnsōs, quī videntur stipem hūmānitātis causā collectam potius in ūsum terroristārum dēstinasse. Feruntur enim sub falsīs caritātis nōminibus octōgiēs centēna mīlia dollarōrum terroristīs dedisse Hamas dictīs. Hispānia Intrā septem diēs quattuor trāminibus ferroviāriīs in Hispāniā variae calamitātēs accidērunt. Quadraginta et trēs hominēs sunt interfectī.

#650 - Salmo 98 - Cante um Novo Tempo - O Louvor que Move a História | JB Carvalho by JB Carvalho

Welcome back to All Things Markets—Michael Novogratz and I are diving deep into the money in politics, the crypto legislation battle unfolding on Capitol Hill, and why the banking lobby might be winning fights it shouldn't. Novo has just returned from Washington with some sobering insights about Citizens United, lobbying power, and why the smart money is betting big on digital assets despite the headwinds. Michael Novogratz is the Founder and CEO of Galaxy Digital. He was formerly a Partner and President of Fortress Investment Group LLC. Mr. Novogratz served on the New York Federal Reserve's Investment Advisory Committee on Financial Markets from 2012 to 2015. He serves as the Chairman of The Bail Project and has made criminal justice reform a focus of his family's foundation. Follow Anthony on X: https://x.com/Scaramucci Follow Novo on X: https://x.com/novogratz Anthony Scaramucci is the founder and managing partner of SkyBridge, a global alternative investment firm, and founder and chairman of SALT, a global thought leadership forum and venture studio. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Mais um conteúdo no ar! Desta vez para falar da Série A, sim, isso mesmo, em janeiro já iniciamos os trabalhos para falar de Brasileirão! Fred Figueiroa e Cássio Zirpoli debatem todas as novidades do campeonato para a temporada 2026, novo calendário, novidades no regulamento, nova geografia, viagens, muitas viagens e muito mais. Ouça agora […]

Think Fresh is back to start the new year with our 2026 Trends & Predictions in a “popcorn” episode! Various members of our team pop in to chat with Jen & Ryan about what they think the biggest trends in their areas of expertise will be in the coming year.    It's also our golden episode!  We celebrate 19 Think Fresh episodes as de Novo turns 19 this month ✨

Confira os destaques de Os Pingos nos Is desta quarta-feira (14):A esposa do governador de São Paulo, Cristiane Freitas, afirmou nas redes sociais que o Brasil precisa de um “novo CEO” ao comentar um vídeo em que Tarcísio de Freitas (Republicanos) defende redução do tamanho do Estado, privatizações e atração de investimentos, criticando a permanência do PT no poder. A pesquisa Genial/Quest, divulgada nesta quarta-feira, aponta que 44% dos brasileiros avaliam que o ex-presidente Jair Bolsonaro errou ao indicar Flávio Bolsonaro (PL) para a disputa presidencial; o levantamento mostra ainda que apenas 22% votariam no nome escolhido, enquanto 49% rejeitariam qualquer indicação e 24% considerariam o apoio sem que fosse decisivo. O governo federal vai disponibilizar 40 smart TVs para penitenciárias federais de segurança máxima a fim de permitir sessões de cinema dentro do projeto ReintegraCINE, coordenado pela Secretaria Nacional de Políticas Penais, que tem como objetivo a reintegração de presos; a pasta afirma que a atividade já existia em outro formato e foi modernizada com a substituição de DVDs e fitas VHS pelos novos equipamentos. O governo do presidente Lula (PT) saiu em defesa do Bolsa Família após declaração da atriz Solange Couto, que afirmou nas redes sociais que o benefício estimularia jovens a abandonar os estudos; a manifestação viralizou e levou o governo a afirmar que o programa não incentiva evasão escolar e que suas regras condicionam o pagamento à frequência escolar das crianças. Durante viagem aos Estados Unidos, Flávio Bolsonaro (PL) transmitiu ao irmão Eduardo Bolsonaro (PL) um recado do ex-presidente Jair Bolsonaro para adotar um discurso mais moderado e evitar confrontos com lideranças do Centrão e nomes presidenciáveis; a orientação ocorre após embates públicos envolvendo o comando do partido e críticas a aliados da direita. O programa Voa Brasil, lançado pelo governo para facilitar viagens aéreas com passagens a R$ 200, comercializou pouco mais de 5 mil bilhetes entre julho de 2024 e janeiro deste ano, número que representa menos de 2% dos 3 milhões de assentos anunciados para o primeiro ano. Você confere essas e outras notícias em Os Pingos nos Is.

Moçambique: Novo aviso vermelho de chuvas muito fortes até sexta-feira. Guiné-Bissau: Atual crise político-militar agrava a situação económica. Angola: Arrancou o mediático julgamento dos arguidos do fisco angolano, o denominado "Caso AGT".

Julie Rovner, chief Washington correspondent for KFF Health News, joins Howie and Harlan to make sense of the fight over ACA subsidies and reflect on her decades of health policy reporting. Harlan reports on a new wave of breakthroughs in obesity treatment; Howie provides updates on the measles outbreak and a record-setting flu season. Show notes: Obesity treatments "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial" "Arrowhead's gene-silencing drugs cut fat in early obesity studies" "Novo launches Wegovy weight-loss pill for sale in US" "Older Americans Quit Weight-Loss Drugs in Droves" Julie Rovner What the Health? podcast What the Health? podcast: "Time's Up for Expanded ACA Tax Credits" What the Health? podcast: "What Do Republicans Really Want on Health Care?" "Trump wants GOP's flexibility on Hyde Amendment" Congressional Research Service: The Hyde Amendment Healthcare.gov: Health Savings Accounts "Republicans unveil health care plan to counter Democratic effort to extend ACA subsidies" 119th Congress: H.R.1 KFF: "The Impact of H.R. 1 on Two Medicaid Eligibility Rules" KFF: "Implementation Dates for 2025 Budget Reconciliation Law" KFF: "Health Care Costs and Affordability" Flu and Measles CDC: Weekly US Influenza Surveillance Report "Flu cases, hospitalizations are rising sharply in CT" Connecticut Department of Public Health: Weekly Respiratory Viral Disease Report CDC: Measles Cases and Outbreaks CDC: Vaccination Coverage and Exemptions among Kindergartners
 In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.

Gospoda in ekipa vam želimo eno zdravo, srečno, uspešno in zabavno 2026

In der ersten Folge des neuen Jahres liefern die Finanzjournalisten Dietmar Deffner und Holger Zschäpitz wieder ihre 26 Investment-Ideen für das Börsenjahr 2026. Der Anspruch ist hoch: In den vergangenen drei Jahren erzielten die Ideen im Schnitt deutlich zweistellige Renditen. Jetzt geht es darum, diese Erfolgsserie fortzuschreiben. DEFFNER & ZSCHÄPITZ sind wie das wahre Leben. Wie Optimist und Pessimist. Im wöchentlichen WELT-Podcast diskutieren und streiten die Journalisten Dietmar Deffner und Holger Zschäpitz über die wichtigen Wirtschaftsthemen des Alltags. Schreiben Sie uns an: wirtschaftspodcast@welt.de Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutzerklärung: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Market update for Monday January 5, 2026Follow us on Instagram (@TheRundownDaily) for bonus content and instant reactions.In today's episode:U.S. oil stocks rally as investors bet on long-term upside in VenezuelaNovo Nordisk launches the first-ever GLP-1 weight-loss pill in the U.S.Mobileye jumps after landing a major U.S. automaker for self-driving techComcast slides as its cable spinoff Versant officially begins tradingCES kicks off in Vegas as tech giants test consumer demand for AI hardware

Novo and Philip (philipchurch.com) discuss their picks for the best of what 2025 had to offer:Best in Seasonal Television – Alien: Earth; PluribusHMs: Andor, The Bear, Severance, Hacks, Running Point, The Paper Best Limited Series in Television – AdolescenceBest in Film – The Life of Chuck; Frankenstein; SinnersHMs: Weapons, Black BagBest in Music – The Omnific; Billy Woods: GolliwogHMs: Sharp Pins - Radio DDR; Balloon Balloon Balloon; Lucrecia Dalt - A Danger to Ourselves; Rochelle Jordan - Through the Wall; Rosalia - Lux; Sudan Archives - The BPM; Mark Pritchard & Thom Yorke - Tall Tales; Deftones - Private Music; Mdou Moctar - Tears of Injustice; Tame Impala - DeadbeatBest in Writing – Current iterations of Batman & Spider-Man Comic Books, specifically the work of Joe Kelly; John Candy: I like Me; The Frank Monologue, written by Mike White, from the White Lotus, Season 3, Episode 5Best in Gaming – Clair Obscur: Expedition 33HMs: Silksong, Thank goodness you're hereBest in Animation – Love Death + Robots, Vol. 4; Bad Guys 2; Kpop Demon HuntersMISC Best of – Podcast "One Strange Thing;" Musical "Hades Town;" NYC Restaurant "Le Bernardin;" Documentary "Penny Slinger: Out of the Shadows"Happy Holidays! Happy New Year! And we'll see YOU in 2026!Thank you for listening! Please consider supporting us with a donation - @novodeproductions on paypal ⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠ Support our colleagues at:Philipchurch.comAlexandra-parsons.com Check out more at www.novodeproductions.com as well, and if you'd like to be on the show, you can contact us at novodeproductions@gmail.com. This Episode is also brought to you by: Novel "Til the Bitter [End]emic" - Available now ⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠ - Til The Bitter [End]emic is a novel about discovery; about what we do, who we become, and what we realize is truly important when we're faced with insurmountable odds, the same kind that makes us face our own mortality. Short story - "Cancel Culture Lotto" - available ⁠⁠⁠⁠here⁠⁠⁠⁠ on Amazon. Short Story "Post Meridiem" - follow entropy sessions character Lydia, one of the lead madams of an Anonymous House, as she manages the ups and downs of a very unique hospitality market, one that specializes in the most sinful of pleasures only the underbelly of society can really offer; you can find “Post Meridiem” on Amazon ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ in all major ebook formats. Novella “Adul(ter)ation” – Now available as an Audiobook ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ - follow adult entertainer Jessica Amber Star as she embarks on a journey that will change her life forever…She not only finds herself in the industry, but figures out a way to transform herself and eventually become…reborn…find out how in Adul(ter)ation, which can be found on Amazon in all major formats. Novel "The Entropy Sessions" - a tale of loss, love, and madness, and our past, present, and future relationships with technology - find it ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ - in paperback, as an ebook on Amazon, or as an audiobook through Audible. Zencastr - our go-to tool to record our podcast with multiple guests remotely. With Zencastr, you can record separate audio and video tracks, and it's all backed up on a secured cloud so you never lose your hard work. It's reliable, easy to use, and there's nothing to download. So go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠zencastr.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and use promo code: artofthebeholder, and get 30% off your first three months with a PRO account. So create your ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ today! #⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠madeonzencastr⁠⁠⁠⁠⁠⁠Note: Only the intro music is by A-CO; all other music or sound effects is stock from various outlets. Main resource for background information: wikipedia.com.

Com Joana Azevedo

No 3 em 1 desta segunda-feira (29), o destaque foi o ex-presidente Jair Bolsonaro (PL), que passou por mais uma cirurgia para conter crises de soluço, com a realização de um bloqueio do nervo frênico. Em coletiva de imprensa, a equipe médica informou que o procedimento foi tranquilo e que Bolsonaro ficará em observação. A expectativa é que ele passe o Réveillon no hospital e receba alta no dia 1º de janeiro. A Polícia Militar de São Paulo prendeu 17 detentos que descumpriram as regras do benefício da saidinha de Natal. Cerca de 30 mil presos foram beneficiados pela medida em todo o estado neste fim de ano. Reportagem: Misael Mainetti. Os Correios preveem economizar até R$ 4,2 bilhões com um novo plano de reestruturação, que inclui corte de despesas, a proposta de demissão de 15 mil funcionários e o fechamento de cerca de mil agências em todo o país. Levantamento do instituto Paraná Pesquisas aponta que o governo Lula (PT) é desaprovado por 50,9% dos brasileiros, enquanto 45,6% aprovam a gestão. Para 42,8%, o governo é ruim ou péssimo; já 32,7% avaliam a administração como ótima ou boa. O valor da passagem de ônibus em São Paulo vai subir de R$ 5,00 para R$ 5,30, enquanto as tarifas do metrô e dos trens passam de R$ 5,20 para R$ 5,40. Os novos valores entram em vigor a partir de 6 de janeiro de 2026. As apostas para a Mega da Virada seguem abertas até quarta-feira (31). O concurso deste ano oferece o maior prêmio da história, estimado em R$ 1 bilhão. Reportagem: Misael Mainetti. Em entrevista à BBC News, o ex-embaixador dos Estados Unidos e especialista em América Latina, John Feeley, avaliou a relação entre Donald Trump e Jair Bolsonaro (PL). Segundo ele, Trump teria abandonado o aliado brasileiro após Bolsonaro deixar de ser politicamente útil. Feeley também afirmou que o recente corte de tarifas não deve ser interpretado como uma vitória do governo Lula (PT). O presidente Donald Trump ofereceu à Ucrânia uma garantia de segurança por 15 anos como parte das negociações para encerrar o conflito com a Rússia. Trump também se reuniu com Benjamin Netanyahu para tratar da situação em Israel. Reportagem: Luca Bassani. Tudo isso e muito mais você acompanha no 3 em 1. Learn more about your ad choices. Visit megaphone.fm/adchoices

The S&P 500 closing at a fresh record high, as commodities come along for the ride. If the metal moves in Gold, Silver, and Copper can keep rocking into the new year, and how this morning's strong GDP report will impact the Fed's next rate decision. Plus Shares of Novo Nordisk on the move as the pharma company's weight loss pill gets approved by the FDA. How the decision can tip the scales for Novo, and what one analyst sees in store for the weight loss drug space.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

David Trainer of New Constructs on what fundamentals are really saying about today's market. Stephen Tusa of JPMorgan breaks down the state of industrials and Alan Ratner of Zelman assessing real estate trends and risks. Our Steve Kovach examines whether artificial intelligence is becoming commoditized faster than investors expected. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Roger Silva foi confirmado como novo técnico e Ítalo Rodrigues como executivo de futebol do Sport. No programa, análise completa das escolhas da nova gestão, do cenário político e das limitações financeiras do clube para 2026. Fred Figueiroa comanda o debate, com comentários de Cassio Zirpoli. Na técnica, João Trigueiro e Marcio Souza. Veja agora […]

Broadcast from KSQD, Santa Cruz on 12-18-2025: Dr. Dawn opens by examining how market competition is actually working in the weight loss drug sector. Novo Nordisk's Ozempic and Wegovy compete against Eli Lilly's Monjaro and ZepBound, with prices dropping nearly 50% as companies launch direct-to-consumer websites. The main barriers remain needles and refrigeration, driving development of oral versions. Novo's Wegovy pill awaits FDA approval for early 2026 launch at $150 monthly. Next-generation drugs show remarkable results: Eli's retatrutide causes 24% weight loss in 48 weeks, while Novo's Cagrisema combines semaglutide with amylin to reduce muscle loss. Pfizer paid $10 billion for Metsera's once-monthly drug despite significant side effects. A quick fiber tip suggests adding plain psyllium to morning coffee for cardiovascular and microbiome benefits. Start with half a teaspoon and work up to two teaspoons (10 grams) over several weeks to avoid gas. The prebiotic fiber improves glucose tolerance and may reduce cancer risk. UC San Diego scientists discovered why cancers mutate so rapidly despite being eukaryotic cells with protected chromosomes. The answer is chromothripsis, a catastrophic event where the enzyme N4BP2 literally explodes chromosomes into fragments. These reassemble incorrectly, generating dozens to hundreds of mutations simultaneously and creating circular DNA fragments carrying cancer-promoting genes. One in four cancers show evidence of this mechanism, with all osteosarcomas and many brain cancers displaying it. This explains why the most aggressive cancers resist treatment. Research from 2013 shows any glucocorticoid use significantly increases venous thromboembolism risk, with threefold increases during the first month of use. The risk applies to new and recurrent clots, affecting both oral and inhaled steroids, though IV poses highest risk and topical the lowest. Joint injections fall somewhere between inhaled and oral. Anyone with prior blood clots should avoid steroids except for life-threatening situations like severe asthma attacks requiring ventilation. A meta-analysis of 20 randomized controlled trials shows creatine supplementation helps older adults (48-84) maintain muscle mass when combined with weight training two to three times weekly. The supplement provides no benefit without exercise. Recommended dosing starts at 2 grams and works up to 5 grams daily. Vegans benefit most since they consume little meat or fish. Important caveat: creatine throws off standard kidney function tests (creatinine), so users should request cystatin C testing instead for accurate renal health assessment. A new JAMA study suggesting risk-based mammogram screening is fatally flawed. First, researchers offered chemopreventative drugs like tamoxifen only to the high-risk group, contaminating the study design. Second, the demographics skewed heavily toward white college-educated women, missing the reality that Black women face twice the risk of aggressive breast cancer with 40% higher mortality. Third, wild-type humans failed to follow instructions—low-risk women continued getting annual mammograms anyway while high-risk women skipped recommended extra screenings. The conclusion of "non-inferior" outcomes is meaningless given poor adherence. Stick with annual mammograms, and consider alternating with MRIs for high-risk women. The EAT-Lancet report condemns red meat based purely on observational data showing correlations with heart disease, cancer, and mortality. But people who eat lots of red meat differ dramatically from low consumers: they weigh more, smoke more, exercise less, and eat less fiber. Studies can't control for sleep quality, depression, or screen time. Notably, heavy meat eaters also die more in accidents, suggesting a risk-taking lifestyle phenotype. The inflammatory marker TMAO is higher in meat eaters, but starch is also pro-inflammatory. Eating red meat instead of instant ramen might improve health. A balanced diet with limited amounts beats epidemiology-based blanket statements. Dr. Dawn grades Dr. Oz's performance as CMS administrator. Starting at minus one for zero relevant experience, he earns plus two for promoting diet, exercise, and gut health on his show. He studied intensively after nomination, calling all four previous CMS directors repeatedly and surrounding himself with experienced staff (plus one). He finalized Medicare rules favoring prevention over surgery and earned bipartisan praise as "a real scientist, not radical" (plus one). He divested healthcare holdings but kept some blind trust interests (minus 0.5). He's developing a CMS app and partnering with Google on a digital health ecosystem (plus one), but supports ending ACA subsidies that will raise premiums for millions (minus one). He correctly promoted COVID vaccines and contradicted Trump's Tylenol-autism claims (plus one). Final score: 3.5 out of 5 possible points, the only positive score for any Trump health administrator.

Felipe Mesquita, Evandro de Freitas e Bruno Carvalho batem um papo sobre as tardes da TV brasileira nos anos 80, 90 e 2000. Esse era o horário em que a televisão se tornava companhia fixa depois da escola, misturando desenhos animados, séries, novelas, programas infantis e atrações populares que ajudaram a moldar uma geração inteira. Nos anos 90, a televisão aberta vivia um momento de enorme força criativa e audiência. Enquanto as manhãs focavam nas crianças, as tardes tinham como foco os jovens. A Sessão da Tarde da Globo e o Cinema em Casa do SBT disputam a atenção dos jovens cinéfilos. A TV Manchete enchia sua programação com animes ("Cavaleiros do Zodíaco") e tokusatsus ("Jaspion" e "Jiraiya"). Junto com isso tinham as reprises de novelas novelas brasileiras no "Vale a Pena Ver de Novo", as novelas mexicanas ("Mario do Bairro" e "A Usurpadora"), programas de fofoca (Sônia Abrão), programas de treta de família ("Casos de Família"), Programa Livre, "Malhação" e muito mais.As tardes da TV brasileira de antigamente representam um período em que a televisão tinha papel central na rotina das famílias. Era um consumo coletivo, sem streaming, sem escolha sob demanda, mas com um sentimento de evento diário. Tudo acontecia ao mesmo tempo para todo mundo.Essa é mais uma edição da nossa série Na TV!==###==- NORDVPN | Tenha uma conexão segura e acesso conteúdos do mundo inteiro! https://nordvpn.com/99vidas- ALURA | Toma aí 20% de desconto na sua assinatura anual! Quer assinar por 2 anos? O desconto é de 40%!!! ! É grande oportunidade para transformar a sua carreira tech!! https://alura.com.br/99vidas

In part 2 of this episode of the HVAC Know It All Podcast, host Gary McCreadie continues his conversation with Jason Esteves, General Manager Americas at Seitron Americas Inc. They explore advanced concepts in combustion analysis, focusing on detecting cracked heat exchangers using oxygen changes and carbon monoxide levels. Jason explains why even a half percent shift in oxygen can signal serious issues and breaks down how combustion behaves in low-fire conditions. The discussion includes real-world examples, challenges with equipment startups, and tips for using analyzers like the NOVO. They also cover practical steps to update the analyzer's firmware for added features. Gary and Jason dive into the real process of spotting cracked heat exchangers using oxygen levels and CO readings. Jason explains how even a small shift in oxygen can mean a big issue and why looking at both O2 and CO is key. They talk through examples from real service calls and explain how low gas flow affects combustion readings. Jason shares why accurate data matters and how techs can avoid mistakes with proper analyzer checks. They end by showing how to update the NOVO tool so techs can use the newest test features in the field.   Expect to Learn: How to detect a cracked heat exchanger using small changes in oxygen levels. Why carbon monoxide readings alone are not enough to confirm a crack. What happens during low-fire conditions and how it affects combustion data. How to check your analyzer for leaks or setup issues before trusting the numbers. How to update the NOVO analyzer with new features right from your computer.   Episode Highlights:  [00:00] - Intro to Jason Esteves in Part 02 [02:25] - Finding & Testing Heat Exchanger Corrosion [04:34] - Oxygen Change: The Key Indicator of a Crack [07:12] - Story: Startup Issues with Makeup Air Units [09:30] - Combustion Analysis with Low Gas Input [11:25] - Importance of Proper Startup and Commissioning [15:47] - Update the NOVO Analyzer for Cracked Heat Exchanger Mode This Episode is Kindly Sponsored by: Master: https://www.master.ca/ Cintas: https://www.cintas.com/ Cool Air Products: https://www.coolairproducts.net/ property.com: https://mccreadie.property.com SupplyHouse: https://www.supplyhouse.com/tm Use promo code HKIA5 to get 5% off your first order at Supplyhouse! Follow the Guest Jason Esteves on: LinkedIn: https://www.linkedin.com/in/jason-esteves-9690255/  Seitron Americas Inc: https://www.linkedin.com/company/seitron-americas-inc/  Website: Seitron Americas Inc: http://www.seitronamericas.com/  Follow the Host: LinkedIn: https://www.linkedin.com/in/gary-mccreadie-38217a77/  Website: https://www.hvacknowitall.com Facebook: https://www.facebook.com/people/HVAC-Know-It-All-2/61569643061429/   Instagram: https://www.instagram.com/hvacknowitall1/ 

In this episode of the HVAC Know It All Podcast, host Gary McCreadie speaks with Jason Esteves, General Manager Americas at Seitron Americas Inc. Jason discusses the critical importance of personal carbon monoxide (CO) detection, sharing stories about real-world situations where CO monitors helped prevent dangerous exposures. He explains how personal CO detectors, designed to stay on continuously, provide safety in environments like boiler rooms, vehicles, and even hotels. The conversation also covers the health risks of long-term CO exposure and the significance of using proper monitoring equipment, especially in HVAC work, to ensure safety on the job. Jason shares insights on the features of CO monitors, including those in the Novo combustion analyzer, and how they help technicians detect problems like cracked heat exchangers. In this episode, Jason Esteves, General Manager Americas at Seitron Americas Inc., talks about the importance of personal carbon monoxide (CO) detection and why it's vital for safety. He explains to Gary how CO detectors can help prevent dangerous exposure in places like vehicles, hotels, and job sites. Jason shares why continuous monitoring is essential and how these devices can protect workers in high-risk environments. They also discuss the risks of long-term CO exposure, the role of combustion analyzers, and how tools like the Novo analyzer can help detect issues like cracked heat exchangers. Jason emphasizes how proper CO monitoring supports safer, healthier working conditions. Expect to Learn: Why personal carbon monoxide (CO) detection is critical for safety in HVAC work. How continuous CO monitoring can protect workers in high-risk environments like vehicles and boiler rooms. Why using the right CO detector is essential to avoid dangerous exposure. How tools like the Novo combustion analyzer help detect issues like cracked heat exchangers. The long-term health risks of CO exposure and why proper detection can prevent serious harm. Episode Highlights: [00:00] - Intro to Jason Esteves in Part 1 [02:22] - Personal CO Detector Story [05:15] - Why Safety Monitors Stay On [08:41] - Real-Life CO Detection Stories [10:55] - CO in Warehouses & Health Risks [14:21] - Citron Detector Alarm Levels [15:35] - Intro to Cracked Heat Exchangers [19:57] - Using O2 to Detect Cracks [24:30] - Novo's Cracked Heat Exchanger Mode   This Episode is Kindly Sponsored by: Master: https://www.master.ca/ Cintas: https://www.cintas.com/ Cool Air Products: https://www.coolairproducts.net/ Property.com: https://mccreadie.property.com SupplyHouse: https://www.supplyhouse.com/tm Use promo code HKIA5 to get 5% off your first order at Supplyhouse!   Follow the Guest Jason Esteves on: LinkedIn: https://www.linkedin.com/in/jason-esteves-9690255/ Seitron Americas Inc: https://www.linkedin.com/company/seitron-americas-inc/  Website: Seitron Americas Inc: http://www.seitronamericas.com/    Follow the Host: LinkedIn: https://www.linkedin.com/in/gary-mccreadie-38217a77/ Website: https://www.hvacknowitall.com Facebook: https://www.facebook.com/people/HVAC-Know-It-All-2/61569643061429/  Instagram: https://www.instagram.com/hvacknowitall1/

⏱️ Timestamps0:07 – What's your futures trading tip of the week?0:09 – The new AI company to watch0:20 – Google AI takeover — is Nvidia under threat?0:48 – Bitcoin buy price0:50 – MicroStrategy's worst 5-month streak since adopting the Bitcoin strategy — sell now or buy of a lifetime?0:55 – If I'm 33 and gave up on buying a home, what should my new “American Dream” be?1:06:00 – China–Taiwan–Japan tensions1:13:00 – Should I put $1M into QQQI or SPYI and live off the dividends?1:15:00 – How to stay disciplined during down markets when targets don't hit1:22:00 – Should you dollar-cost average or wait for drops?1:29:00 – Novo's epic fall1:36:00 – Dogecoin failure + U.S. national debt crisisThis week on Market Mondays, we covered everything from futures trading plays to the newest AI company threatening Google and Nvidia's dominance. We broke down the real Bitcoin buy levels, MicroStrategy's worst 5-month streak ever, and whether this is a red flag or the buying opportunity of a lifetime. We also discussed what the “American Dream” should look like today if homeownership feels out of reach, and whether dropping $1M into QQQI or SPYI for monthly dividend income is a smart path to financial freedom. Plus, we examined global tensions between China, Taiwan, and Japan, and the impact these conflicts could have on markets in the coming years.We also dove deep into investor psychology — how to stay disciplined when targets don't hit, how to avoid FOMO during red markets, and whether to dollar-cost average or wait for pullbacks in 2025. We covered Novo's epic fall, Dogecoin's collapse, and the growing national debt crisis that could reshape investor strategy for the next decade. If you missed this one, it's a must-watch for anyone serious about building wealth in a chaotic economy.Market Mondays Black Friday Deal (Limited to First 50): https://marketmondaysdeal.com#MarketMondays #EarnYourLeisure #Investing #Bitcoin #Stocks #Nvidia #GoogleAI #ETFs #DividendInvesting #WealthBuilding #Crypto #MSTR #Finance #EYLOur Sponsors:* Check out Square: https://square.com/go/eylSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy